Clinical Trials - analysis End-points, planned and unplanned secondary analyses, interim analyses, stopping rules Dick Menzies, MD Respiratory Epidemiology. - ppt download
Suggested trial design (with interim analysis for futility). | Download Scientific Diagram
RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida - RenovoRx
CLINICAL STUDY REPORTING - Assessing the Value of Interim Analyses in Clinical Trials
Interim Analysis - an overview | ScienceDirect Topics
Randomised trials at the level of the individual - The Lancet Global Health
On Biostatistics and Clinical Trials: VALOR Trial - A Successful and Failed Phase III Study with Adaptive Sample Size Re-stimation for Promising Zone
PPT - Interim Analysis PowerPoint Presentation - ID:2495631
New approaches to clinical trials: Adaptive designs - EUPATI Toolbox
JCM | Free Full-Text | Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials
Sample size reassessment. Notes: If the first interim analysis shows... | Download Scientific Diagram
Interim analysis in clinical trials (1)
When is it feasible to do an interim analysis in a clinical trial?
PPT - Interim Analyses of Clinical Trials PowerPoint Presentation - ID:2135170
Evaluating Clinical Trial Designs for Investigational Treatments of Ebola Virus Disease | PLOS Medicine
Key design considerations for adaptive clinical trials: a primer for clinicians | The BMJ
Development and Evaluation of a Simulation-Based Algorithm to Optimize the Planning of Interim Analyses for Clinical Trials in ALS | Neurology
Frontiers | Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers
Stopping a trial early in oncology: for patients or for industry? - Annals of Oncology
Biostatistics Study Design | Precision for Medicine
Hidden Consequences of Interim Analyses & Adaptive Trial Options - Quantics Biostatistics
Program in Regulatory Science Clinical Trial Designs - Dana-Farber Cancer Institute | Boston, MA
The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias | BMC Medical Research Methodology | Full Text
Validation of Predictive Analyses for Interim Decisions in Clinical Trials | JCO Precision Oncology
